Total: $185.49M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Antares Pharma Inc. (MEDJ)

Private placement of common stock

0.5S

$3

Antares completed the final $3M of a $10M private placement; the first $7M was raised in early February (3/6)

Atlantic Technology Ventures Inc. (ATLC)

Common stock purchase agreement

N/A

$6

Fusion Capital Fund II LLC bought $6M of Atlantic's common stock (3/19)

Axys Pharmaceuticals Inc. (AXPH)

Exercise of options for common stock

2.4S

N/A

Bay City Capital acquired about 2.4M shares of Axys common stock through the exercise of options (3/19)

CollaGenex Pharmaceuticals Inc. (CGPI)

Private placement of common stock

1.5S (plus warrants to purchase 0.4S)

$7.5

CollaGenex closed a $7.5M equity financing with the sale of 1.5M shares at $5 per share and warrants to purchase 400,000 shares at $6 per share (3/13)

Helix BioPharma Corp. (Canada; TSE:HBP)

Exercise of warrants

1.23W

C$3.93 (US$2.56)

Helix raised US$2.56M through the exercise of 1.23M Series A warrants, which resulted in the issuance of 1.23M common shares at C$3.50 per share (3/6)

Hyseq Inc. (HYSQ)

Drawdown of credit line

N/A

$20

Hyseq drew down $20M available under its line of credit with company chairman George Rathmann (3/21)

IGEN International Inc. (IGEN)

Private placement of common stock

0.79S

$9.5

IGEN sold 789,075 shares for $9.5M to Acqua Wellington North American Equities Fund Ltd. under an equity financing agreement struck in February covering the sale of up to $60M of IGEN's stock over 28 months (3/16)

Martek Biosciences Corp. (MATK)

Private placement of common stock

1.28S (plus warrants to purchase 0.3S)

$20

Martek raised $20M in the financing; J.P. Morgan H&Q acted as placement agent for the financing; the warrants have a five-year term and are exercisable immediately at $19.05 per share (3/2)

MGI Pharma Inc. (MOGN)

Flexible underwritten equity facility

N/A

­

MGI Pharma made an arrangement to sell up to $100M in stock from shelf-registration shares to Ramius Securities LLC over a two-year period (3/1)

Nastech Pharmaceutical Co. Inc. (NSTK)

Private placement of common stock

0.86S

$4.2

Nastech raised about $4.2M through a private sale of 860,000 shares to investors, including Safeco Growth Opportunities Fund and an asset management division of a money center bank; Jesup & Lamont Securities Corp. acted as placement agent (3/22)

NeoTherapeutics Inc. (NEOT)

Private placement of common stock and warrants

1.25S and 0.125W

$5

NeoTherapeutics raised $5M in a private placement with IAT ReInsurance Syndicate Ltd. (3/14)

Oxford BioMedica plc (UK; LSE:OXB)

Private placement of common stock

172.3S

#27 (US$39.53)

Oxford expected to raise US$39.53M in a private placement being underwritten by N.M. Rothschild & Sons Ltd., and Beeson Gregory Ltd. (3/12)

Triangle Pharmaceuticals Inc. (VIRS)

Private placement of Series B preferred stock

0.2S

$12

Triangle raised $12M through the sale of 200,000 Series B preferred shares to an undisclosed group of investors; the $12M was added to a $46.2M private placement announced in January; Bank of America Securities LLC served as placement agent (3/12)

V.I. Technologies (VITX)

Private placement of common stock

1.6S

$10

V.I. Technologies raised $10M in the equity placement with the State of Wisconsin Investment Board (3/5)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

LSE = London Stock Exchange; TSE = Toronto Stock Exchange

N/A = Not available or reported.

@ Dates refer to the date of the press release.